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Abstract 
Background: Despite the significant gains made globally in reducing the burden of malaria, the disease remains a 
major public health challenge, especially in sub‑Saharan Africa (SSA) including Ghana. There is a significant gap in 
financing malaria control globally. The private sector could become a significant source of financing malaria control. 
To get the private sector to appreciate the need to invest in malaria control, it is important to provide evidence of 
the economic burden of malaria on businesses. The objective of this study, therefore, was to estimate the economic 
burden on malaria on businesses in Ghana, so as to stimulate the sector’s investment in malaria control.
Methods: Data covering 2012–2014 were collected from 62 businesses sampled from Greater Accra, Ashanti and 
Western Regions of Ghana, which have the highest concentration of businesses in the country. Data on the cost of 
businesses’ spending on treatment and prevention of malaria in staff and their dependants as well as staff absentee‑
ism due to malaria and expenditure on other health‑related activities were collected. Views of business leaders on 
the effect of malaria on their businesses were also compiled. The analysis was extrapolated to cover 5828 businesses 
across the country.
Results: The results show that businesses in Ghana lost about US$6.58 million to malaria in 2014, 90 % of which 
were direct costs. A total of 3913 workdays were lost due to malaria in firms in the study sample during the period 
2012–2014. Businesses in the study sample spent an average of 0.5 % of the annual corporate returns on treatment of 
malaria in employees and their dependants, 0.3 % on malaria prevention, and 0.5 % on other health‑related corpo‑
rate social responsibilities. Again business leaders affirmed that malaria affects their businesses’ efficiency, employee 
attendance and productivity and expenses. Finally, about 93 % of business leaders expressed the need private sector 
investment in malaria control.
Conclusions: The economic burden of malaria on businesses in Ghana cannot be underestimated. This, together 
with business leaders’ acknowledgement that it is important for private sector investment in malaria control, provides 
motivation for engagement of the private sector in financing malaria control activities.
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Background
Globally, there has been a notable reduction in the bur-
den of malaria as evidenced by 2015 estimates compared 
to 2000 estimates. For instance, the total number of 
cases, incidence and deaths have reduced by 18, 37 and 
48 %, respectively [1]. The mortality rate has also reduced 
by 60 % over the same period. Within sub-Saharan Africa 
(SSA), deaths in children under-five years reduced by 
57.9  %, displacing malaria to fourth place in terms of 
cause of deaths. Despite these significant gains, malaria 
remains a major public health challenge in SSA—about 
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88 % of the total global cases and 90 % of deaths in 2015 
occurred in the region [1]. In 2015, about 10 % of under-
five deaths in SSA could be attributed to malaria [1].
In Ghana, malaria accounted for about 38 % of outpa-
tient visits and 27.3  % of admissions in health facilities 
and 48.5 % of under-five deaths in 2015, remaining one of 
the leading causes of morbidity and mortality [2]. Ghana 
and nine other countries in SSA accounted for more than 
60 % of malaria deaths in SSA in 2012 [3].
Studies have shown that malaria imposes significant 
burden on the economy of developing countries [4–7]. 
Gallup and Sachs [8] estimated the economic burden of 
malaria on African countries to be up to US$12 billion 
annually and that between 1965 and 1990, economic 
growth in developing countries reduced by 1.3  % per 
person per year due to malaria, whereas McCarthy et al. 
[9] put the reduction in economic growth due to malaria 
at 0.25  % [9]. Other estimates show that gross domes-
tic product (GDP) of many developing countries could 
reduce by 5–6 % due to malaria [10].
Studies have argued that the economic benefits sig-
nificantly reducing or eliminating malaria are enormous. 
Purdy et  al. argue that if appropriate investments are 
put into malaria control globally, the net present value 
of benefits (over costs) that would accrue by 2035 could 
be US$208.6 billion [11]. The World Health Organiza-
tion (WHO) estimates that although costs of investing 
in malaria elimination between 2016–2030 could reach 
US$101.8 billion (with another US$673 million invested 
in research and development annually), the returns on 
such investment could be 40:1 globally and 60:1 for 
SSA, implying, for example, that for every US$1 spent, 
economic gains of US$40 or US$60 would be accrue 
[12]. Similarly, other estimates show that about US$90–
US$120 billion are required to eradicate malaria be by 
2040, and investments to reduce 50  % of the malaria 
burden globally could generate economic returns of 36:1 
[13]. In terms of the impact of malaria on individuals, 
Bleakley estimate that malaria infection during child-
hood reduced adult incomes by about 50  %. Further, 
studies have shown that a 10 percentage point reduction 
in malaria incidence could raise literacy 1–2 percentage 
points [14] and 2.5–5.6 percentage points [15].
Malaria is known to affect businesses in many ways; 
reduced productivity due to increased worker absentee-
ism, increased health care spending, which all impact 
business returns and tax revenue to the state [7, 16]. The 
2011 Roll Back Malaria Report indicates further that in 
SSA, 72  % of businesses reported a negative malaria 
impact, with 39 % perceiving these impacts to be serious. 
The report also indicated nearly 75 % of businesses in the 
Africa region reported that malaria was negatively affect-
ing their business in a survey conducted in 2004.
In Ghana, past estimates of the economic burden 
of malaria on households and the economy abound. 
Asante and Asenso-Okyere [17] estimated that a 1  % 
increase in malaria morbidity reduces economic growth 
by about 0.41  %, and that an episode of malaria costs 
households US$15.79 (in 2003 dollars). Abotsi [18] 
also estimated that an episode of malaria costs house-
holds between US$10.20 (uncomplicated malaria) 
and US$46.62 (severe malaria) (in 2007 dollars). Fur-
thermore, Sicuri et  al. [19] found that households 
spent between US$5.70 (uncomplicated malaria) and 
US$48.73 (severe) in Ghana.
Current estimates of the economic burden of malaria 
on businesses in SSA in general, and Ghana in particu-
lar, are limited. In 2004, AngloGold Ashanti (a mining 
company in Ghana) incurred up to $55,000 per month 
on treatment of malaria in its employees and their 
dependants [20]. Further, 30  % of business leaders who 
responded to a survey in Ghana reported that malaria 
had a strong impact on productivity [21]. The cost esti-
mates by AngloGold Ashanti, nonetheless, represents 
only direct company expenses on treatment and not 
the valued productive losses the business incurs due to 
absenteeism.
The purpose of this study, therefore, is to estimate the 
economic burden of malaria on businesses in Ghana. 
Such clear estimates are essential as advocacy tools to 
stimulate private sector involvement in malaria control in 
the country, especially as donor funds are reducing due 
to the country’s current status as a lower-middle income 
country. In addition, the estimates could be used to cre-
ate awareness and sensitize businesses that it is economi-
cally beneficial to invest in malaria control.
Methods
Study design
The study was a cross-sectional study employing quan-
titative methods to collect expenditure and other cost 
related data from selected businesses and interviews to 
elicit views from senior managers.
Study sites
The study was conducted in three out of the ten regions 
of Ghana; Ashanti, Greater Accra and Western regions. 
Available business statistics indicate that these regions 
have the largest number of businesses with variation 
in types and sizes of businesses in the country. Further, 
malaria prevalence in the study regions are 39  % (the 
third highest prevalence) in Western Region, 16.6  % 
(third lowest) in Ashanti Region and 11.2 % (the lowest) 
in Greater Accra Region. Thus, in terms of the burden of 
malaria, the study regions are spread across the distribu-
tion [22].
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Study population
The study population comprises of all businesses within 
the selected regions registered with the Association of 
Ghana Industries (AGI) and the Ghana Employers Asso-
ciation (GEA), the two largest association of businesses 
in the country
Sample and sampling procedure
The sample size was purposively determined in consul-
tation with the National Malaria Control Programme. It 
was anticipated that 15–20 businesses per region would 
suffice to estimate the burden of malaria on businesses. 
Names of businesses were obtained from Association of 
Ghana Industries (AGI) and Ghana Employers Associa-
tion (GEA) Members’ catalogue. Ashanti, Greater Accra 
and Western regions were purposively selected due to the 
high concentration of businesses in these three regions. 
The businesses in each region were then listed and 
sorted alphabetically by business sectors in Microsoft 
Excel. The businesses were then purposively selected and 
grouped into agriculture and agribusinesses, financial, 
manufacturing and processing and services according to 
categorization of businesses in the economy. The num-
ber of businesses that responded within the data collec-
tion period by region were as follows: Ashanti (n = 23), 
Greater Accra (n =  16) and Western (n =  23) out of a 
total of 909 businesses registered with the two business 
associations in Ghana.
Cost data collection
Data were collected in June/July 2015. Semi-structured 
questionnaires were used for data collection. The data 
collected covered the period from 2012 to 2014. Two 
types of questionnaire were designed for data collec-
tion. The first was to obtain information for estimating 
direct and indirect cost of malaria on businesses. These 
covered: (1) general information on businesses; (2) busi-
nesses’ income and volume of production; (3) direct cost 
of illnesses (malaria and others); and (4) indirect cost of 
illnesses (malaria and others). The second questionnaire 
covered other effects of malaria illness on businesses that 
could not be directly quantified. These were administered 
to Chief Executive Officer/Director, Finance Manager, 
Operations Manager and Human Resource Manager 
through interviews. Research Assistants vetted the filled 
questionnaires for completeness.
Data analysis
The analysis focused on direct costs, indirect cost and 
other effects of malaria. The direct cost comprised 
of expenses incurred by the business on: (a) all direct 
treatment cost of reported illness among staff and 
their dependants; (b) the direct cost of prevention and 
treatment of malaria (i.e. employees and their depend-
ants); and (c) the proportion of direct cost of all illnesses 
due to malaria. The indirect cost (i.e. productivity losses) 
comprised of: (a) total reported days of absenteeism due 
to ill-health; (b) reported absenteeism due to malaria; 
(c) proportion of reported absenteeism due to malaria; 
(d) estimated productivity loss of the business due to ill-
health; (e) estimated productivity loss of the business due 
to malaria; and (f ) estimated reduction in productivity 
of the business due to malaria. Productivity costs were 
estimated by multiplying the number of work days lost 
(i.e. absenteeism due to malaria) by the national mini-
mum daily wage rate. Absenteeism due to malaria was 
calculated using data from firms who had records on 
how many days their workers lost due to malaria. For the 
firms who had no records, estimates on average absen-
teeism due to malaria out of total absenteeism due to 
ill-health we used estimates from the NMCP and other 
studies were used to estimate the total work days lost due 
to malaria.
These costs and work days lost were systematically 
compiled under appropriate cost categories and the total 
costs, average costs and proportions estimated. Based on 
these sample costs, a national ill-health and malaria cost 
to businesses was estimated as the average ill-health and 
malaria costs to business multiplied by the total number 
of businesses (5828 in all) in the country. Where data 
were not available for specific business types, average 
numbers and costs for the given sector were applied.
The other burden (not quantified) of malaria mor-
bidity on businesses in terms of its impact on business 
operations, views on investments in malaria control, and 
business expenditure on malaria control activities were 
grouped into emerging themes and tabulated according 
to business sectors.
The total cost of malaria to businesses was obtained 
as a summation of the direct expenditure on malaria 
and the valued loss productivity costs. The other effects 
were described as these could not be quantified. All costs 
were measured in the appropriate year and adjusted into 
2014 GHS using consumer price indices for health goods 
for the respective years. Then, GHS values were con-




In terms of size, the businesses included in the study 
sample had a total workforce of 8141 of which about 
69 % were males (Table 1). About 41 % of the employees 
were in businesses in the Greater Accra Region, 25 % in 
Ashanti Region and 34  % in Western Region. In terms 
of business sectors, the services sector accounted for 
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Over the three-year period, the average reported cases 
of malaria for all sectors was 22–25  % among employ-
ees and 21–30 % among dependants. The lowest burden 
was recorded in the financial sector i.e. 4–18  % among 
employees and 13–17 % among dependants. The highest 
burdens were 38  % among employees in the construc-
tion and engineering (2014) and pharmaceutical sectors 
(2012) and 39 % among dependants in the construction 
and engineering sector (2014). Figure  1 further shows 
that for 2014, the reported case burdens among employ-
ees was 38 % (construction and engineering), 31 % (phar-
maceuticals), 30  % (agriculture and agribusiness), 18  % 
(financial), 17  % (manufacturing and processing) and 
16 % (services). On average, 2014 saw the highest burden 
among employees. Again, the burden among dependants 
was higher than employees for services, manufacturing 
and processing, and financial sectors whereas the reverse 
holds for construction and engineering and pharmaceu-
ticals sectors. For the agriculture and agribusiness sec-
tor, the average burden was the same for employees and 
dependants.
Cost burden of malaria
Table  2 shows that the total cost of malaria to busi-
nesses within the study sample for 2012–2014 was 
US$288,033.61, about 93 % of which was direct cost and 
about 7 % indirect cost.
The estimated economic cost of malaria to businesses 
in Ghana in 2014 was US$6,588,729.09 (Table 3). Of this 
total, direct cost constituted 90 % and indirect cost con-
stituted 10  %. Table  3 further shows that the economic 
burden was highest for businesses in the services sector 
(32  %), followed by businesses in the construction and 
Table 1 Background characteristics of study businesses
Indicator N %
Total no. of employees 8141 100
No. of employees by gender
 Male 5644 69.3
 Female 2497 30.7
No. of employees by sectors
 Construction and engineering 420 5.2
 Services 3825 47.0
 Manufacturing and processing 1335 16.4
 Financial services 57 0.7
 Pharmaceutical 537 6.6
 Agriculture and agribusiness 1967 24.2
No. of employees by region
 Greater Accra 3304 40.6
 Ashanti 2026 24.9

































































































Fig. 1 Percentage of employees and dependants who reported malaria
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engineering sector (about 22  %), financial sector (about 
21 %) and lowest for businesses in the manufacturing and 
processing sector (about 2 %).
Corporate expenditure on malaria treatment
On average between 2012 and 2014, the businesses in the 
sample spent 0.5  % of their gross returns on the treat-
ment of malaria in their employees and dependants. The 
sectoral spending ranges between 0.1  % in manufactur-
ing and processing to 0.9 % in services. In terms of annual 
averages, 2012 saw the highest average corporate spend-
ing on malaria treatment (0.6 %), driven by the construc-
tion and engineering and services sectors, which spent 
1.2  % each of their gross returns on malaria treatment. 
Overall, businesses in the manufacturing sector spent the 
lowest on malaria treatment in 2012 i.e. 0.05 % (Table 4).
Corporate expenditure on malaria prevention activities
Table  5 shows that on average between 2012 and 2014, 
the businesses in the sample spent 0.3  % of their gross 
returns on malaria prevention activities. The sectoral 
spending ranges between 0.1  % for services, construc-
tion and engineering and agriculture and agribusiness 
and 0.6 % in manufacturing and processing. In terms of 
annual averages all sectors spent annual average of 0.3 % 
for each year. Overall, businesses in the service sector 
spent the lowest of 0.04 % in 2012 on malaria prevention 
activities.
Corporate expenditure on other health‑related corporate 
social responsibilities
On average between 2012 and 2014, the businesses 
spent 0.5  % of their gross returns on health related 
corporate social responsibility (CSR). The sectoral 
spending ranges between 0.1  % in pharmaceuticals, 
agriculture and agribusiness and construction and 
engineering and processing to 1.3  % in services. In 
terms of annual averages, 2014 saw the highest aver-
age corporate spending of 0.8 %, driven by the services, 
financial, manufacturing and processing who spent 
more than 1 %. Overall, businesses in the pharmaceuti-
cal sector spent the lowest of 0.02 % in 2014 on other 
health-related CSR (Table 6).
Figure 2 shows that the manufacturing and processing 
and financial sectors spent more on malaria prevention 
activities between 2012 and 2014 compared to malaria 
treatment. Also services, manufacturing and process-
ing and financial sectors reported higher expenditure 
on other health-related CSRs than malaria prevention 
and treatment. Furthermore, agriculture and agribusi-
ness, construction and engineering, and pharmaceutical 
sectors expended more of corporate returns on malaria 
treatment than malaria prevention or other health-
related CSR (Fig. 2).




2012 2013 2014 Total Cost 
profile 
(%)
Direct 99,406.85 96,429.05 73,436.74 269,272.64 93.4
Indirect 6265.12 6851.74 5644.11 18,760.97 6.6
Total 105,671.97 103,280.80 79,080.84 288,033.61 100.00
Table 3 Estimated costs (US$) of malaria to businesses by sector, 2014
Sectors No. of businesses Average cost (US$) Total cost (US$) Cost profile
Direct Indirect Direct Indirect Total
Agriculture and agribusiness 291 1906.60 69.85 554,819.29 20,325.11 575,144.41 8.7
Construction and engineering 453 3092.32 170.58 1,400,820.19 77,271.55 1,478,091.74 22.4
Financial 847 1138.94 519.37 964,681.41 439,903.06 1,404,584.47 21.3
Man. and processing 254 553.48 57.46 140,583.95 14,593.66 155,177.61 2.4
Pharmaceuticals 456 1762.21 145.16 803,569.84 66,190.94 869,760.77 13.2
Services 3527 585.25 11.85 2,064,186.44 41,783.66 2,105,970.10 32.0
Total 5828 – – 5,928,661.12 660,067.97 6,588,729.09 100.0
Table 4 Malaria treatment as  percentage of  gross returns 
on businesses
Sector 2012 2013 2014 Sector average
Agriculture and agribusiness 0.2 0.1 0.2 0.2
Construction and engineering 1.2 0.4 0.8 0.8
Financial 0.1 0.3 0.2 0.2
Manufacturing and processing 0.05 0.1 0.1 0.1
Pharmaceuticals 0.7 0.9 0.6 0.7
Services 1.2 0.9 0.5 0.9
Average 0.6 0.5 0.4 0.5
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Productive days lost by businesses due to malaria
Over the period 2012–2014, the businesses in the study 
sample (i.e. 62 businesses across the three regions) lost a 
total of 3913 workdays due to malaria (Table 7). The low-
est days lost was recorded by manufacturing and process-
ing (54  days) and highest by services (1620  days). The 
agriculture and agribusiness and services sectors together 
accounted for 77 % of the total workdays lost. The high-
est number of work days lost was recorded in 2014 (i.e. 
1530  days). Table  8 presents the workdays lost by staff 
category. Table 8 shows that 73 % of the total workdays 
lost was recorded in junior staff followed by 17 % in sen-
ior staff and 10  % in management. Figure  3 shows that 
overall, malaria accounted for 40  % of productive days 
lost due to illnesses in all sectors. This ranges from 23 % 
in manufacturing and processing to 59 % in services.  
Other effects/burden of malaria
Effect of malaria on business operations
Figure 4 shows that a higher proportion of business lead-
ers from the study sample reported that malaria affected 
efficiency (43 %), employee attendance and productivity 
(38 %) and expenses (46 %). About 59 % further reported 
that malaria did not affect their corporate image while 
about 47  % reported being indifferent to the effect of 
malaria on workload.
Business leaders (Chief Executive Officer/Managing 
Directors, Operations managers and Human Resource 
managers) representing the sample of 62 businesses 
expressed the view that employee absenteeism due 
to malaria affected their businesses through reduced 
workforce productivity, reduced business outputs 
and increased operation cost (through high medical 
expenses). They also indicated that worker absenteeism 
distorts their timelines and targets/production chain.
Asked whether it is worthwhile for government to 
increase investments in malaria control, about 98  % of 
the 130 business leaders responded in the affirmative 
and explained that such increased investments would 
reduce morbidity and mortality, boost business out-
puts and improve economic growth. Asked whether it 
Table 5 Expenditure on  malaria prevention activities 
as percentage of gross returns
Sector 2012 2013 2014 Sector average
Agriculture and agribusiness 0.1 0.1 0.1 0.1
Construction and engineering 0.1 0.1 0.1 0.1
Financial 0.4 0.6 0.3 0.4
Manufacturing and processing 0.5 0.5 0.8 0.6
Pharmaceuticals 0.5 0.8 0.2 0.5
Services 0.0 0.1 0.1 0.1
Average 0.3 0.3 0.3 0.3
Table 6 Expenditure on  other health-related corporate 
social responsibilities
Sector 2012 2013 2014 Sector average
Agriculture and agribusiness 0.1 0.1 0.2 0.1
Construction and engineering N/A 0.2 0.1 0.1
Financial 0.3 0.6 1.3 0.7
Manufacturing and processing 1.0 0.5 1.0 0.8
Pharmaceuticals 0.1 0.2 0.0 0.1
Services 0.3 1.6 2.0 1.3
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Fig. 2 Proportion of spending on malaria treatment, prevention and other CSR
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is worthwhile for their specific businesses to invest in 
malaria control activities, about 93  % of the business 
leaders responded in the affirmative.
Discussion
The study findings show that during the period 2012–
2014, the total cost of malaria to businesses in the study 
sample was US$288,033.61, 93  % of which constituted 
direct costs. Extended to the total number of businesses 
in the country, the estimated cost of malaria to busi-
nesses in Ghana in 2014 was about US$6.58 million, 90 % 
of which were direct costs. Estimates of the economic 
cost of malaria to businesses in developing countries, 
especially sub-Saharan Africa, are rare. Studies have 
estimated the economic cost of malaria on the Ghana-
ian economy—US$50.05 million in 2002 costs by Asante 
and Asenso-Okyere [17]; US$66.9 million in 2009 costs 
by Sicuri et al. [19]; reductions in malaria would increase 
economic growth by 0.07 % bringing in additional annual 
incomes of US$279–US$298 million (2007 costs) over 
30  years [23]. However, most of these studies do not 
account for the cost of malaria to businesses in their 
analyses mainly because of data limitations, i.e. difficult 
to find malaria-specific morbidity and mortality data at 
firm level but also most firms are normally either unwill-
ing or uncomfortable releasing data on business output 
and returns for such purposes.
Further, for the period 2012–2014, a total of 3913 
workdays were lost due to malaria in the 62 firms that 
constituted the study sample, implying that on aver-
age, each business lost about a month’s productivity per 
year due to malaria. About 73  % of the total workdays 
lost represented productive losses in junior staff. This is 
significant because more often, junior staff are directly 
linked to production levels in many firms. Thus, this sig-
nificant burden on them directly impacts the output of 
firms. In terms of sectoral analysis, the services sector 
constituted about 41  % of the total workdays lost, fol-
lowed by agriculture and agribusiness sector with 36 %. 
According to the Ghana Statistical Service [24], services 
Table 7 Annual productivity days lost due to malaria
Sector 2012 2013 2014 Total Period average
Agriculture and agribusi‑
ness
339 448 607 1394 35.6
Construction and engi‑
neering
151 211 209 571 14.6
Financial 35 22 93 150 3.8
Manufacturing and 
processing
23 19 12 54 1.4
Pharmaceuticals 41 39 44 124 3.2
Services 582 473 565 1620 41.4
Total 1171 1212 1530 3913 100.0
Table 8 Productive days lost by staff category
Staff category 2012 2013 2014 Total Period average
Junior staff 873 888 1092 2853 72.9
Senior staff 203 228 232 663 16.9
Management 95 96 206 397 10.1
































Fig. 3 Proportion of productivity days lost due to malaria by sector
Page 8 of 10Nonvignon et al. Malar J  (2016) 15:454 
and agriculture were the first and third largest sectors in 
the Ghanaian economy in 2013, contributing 49.5 and 
22.0 %, respectively, to GDP. Thus, the loss of more than 
1300 workdays in each sector (i.e. in only 62 businesses) 
should be a source of worry to not only government but 
also businesses.
Furthermore, this study found that during the period 
2012–2014, business spent about 0.5 % of annual corpo-
rate returns on treatment of malaria in employees and 
their dependants, with the services sector spending about 
1  % and manufacturing sector spending about 0.1  % 
annually. These estimates may seem insignificant. How-
ever, for large businesses, these translate into significant 
costs to business, thereby raising overall cost of produc-
tion and potentially reducing profits. Using this analogy, 
businesses could save more by raising their spending on 
prevention of malaria (which stood at 0.3 % per annum 
between 2012 and 2014) as reduction in malaria due to 
such efforts would lead to reductions in medical expenses 
and overall cost of production and, consequently lead to 
improved returns. Such efforts would appear costly over 
the short term. However, over a longer term, these would 
lead to appreciable improvements in business profits.
It is important to note that the study finds that the ser-
vices sector which spent the least proportion of gross 
returns on malaria prevention activities spent the largest 
on malaria treatment in employees and their dependants. 
The reverse holds for the manufacturing and processing 
sector—which spent the largest of 0.6 % of gross returns 
on malaria prevention over the study period and spent 
the least on malaria treatment in employees and their 
dependants. The current study did not attempt to model 
the relationship between business spending on malaria 
prevention and treatment. However, it follows that if 
a business spends more on preventing malaria at the 
workplace and within the communities they operate, its 
employees and dependants would have reduced burden 
of malaria. It would be interesting for further studies to 
map out the specific activities that businesses undertake 
with respect to malaria prevention and also other health-
related CSRs.
The survey of leaders of the businesses in the study 
sample indicates that businesses have a clear understand-
ing malaria affects their businesses in various ways. They 
indicated that employee absenteeism due to malaria (in 
employees but also in their dependants) affected their 
businesses through reduced workforce productivity, 
reduced business outputs and increased operation cost 
(through high medical expenses). They also indicated 
that worker absenteeism distorts their timelines and 
targets/production chain. Beyond worker absenteeism, 
business leaders further indicated that malaria had nega-
tive impacts on the efficiency of their businesses and on 
their overall expenses through increased medical bills.
The overwhelming majority (98  %) of business lead-
ers expressed the opinion that there is the need for 
increased government investments in malaria control. 
Such increased investments, they believe, would improve 
health and social wellbeing through reduced morbid-
ity and mortality, which would then improve participa-
tion of households in income generating activities that 
could reduce poverty, but also more school days that 
could increase education outcomes in the longer term. 
On businesses, business leaders indicated that increased 
government investments in malaria control would 
reduce worker absenteeism and improve workforce pro-
ductivity. A combined effect of improved productivity 
and reduced production cost (as a result of savings in 
medical expenses, etc.) would improve business prof-
its, which would have two effects—increase corporate 




























Not at all Indifferent Very much
Fig. 4 Effect of malaria on business operations
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tax to government and attract investors into the sector 
due to profitability, which could further boost corporate 
taxes, thereby enhancing government revenue. Improved 
business output and government revenue would lead 
to improved economic outlook and enhance economic 
growth.
These findings are consistent with the views of business 
leaders worldwide; 22 % of 8000 business leaders world-
wide reported that malaria negatively impacted their 
businesses; 72 % of respondents from SSA reported that 
malaria affected their businesses, with 40 % reporting that 
malaria had “serious detriments” on their businesses [10, 
11]; out of the 119 respondents from Ghana in the same 
survey, 30  % reported that malaria impacts productiv-
ity; respondents concurred that reduced malaria burden 
would improve productivity, reduce costs of production, 
improve sales and widen opportunities for marketing [10].
The study further finds that the overwhelming major-
ity (93 %) of the business leaders surveyed responded that 
it is worthwhile for their businesses to invest in malaria 
control. This finding is important and forms the basis for 
the involvement of the private sector in malaria control. 
Private sector involvement in malaria control may come 
in different forms; businesses may be engaged to con-
tribute to a national pool of funds to be used in scaling 
up current interventions; groups of businesses located 
within same communities may be engaged to support 
malaria control activities within their catchment com-
munities i.e. financial support for interventions, such as 
indoor residual spraying and insecticide-treated bed net 
distribution, within their communities. Businesses may 
also be involved in malaria control through education 
and campaigns (through production and distribution of 
information, education and communication materials) 
directed towards their staff and dependants, clients and 
their immediate communities. Research and develop-
ment (R&D) are a crucial part of efforts toward malaria 
control and elimination. Therefore, businesses may be 
engaged to support R&D through support for research 
into specific aspects of malaria control and training.
It is important to note that a key limitation faced by the 
current study relates to the data from businesses; some 
large businesses were unwilling to be part of the study. 
For those who were part, many reported a lack of specific 
data on malaria morbidity and costs. Thus, for these busi-
nesses, we used the national estimates of proportion of 
malaria to estimate malaria morbidity (out of total mor-
bidity) and costs. It is also important to note that the 
national estimates of costs only involved businesses reg-
istered with the Association of Ghana Industries and the 
Ghana Employers Association. However, there are busi-
nesses that may not be part of these two bodies, which 
were excluded from the analysis. Consequently, the 
estimates from this study are likely to be an underestima-
tion of the true economic cost of malaria to businesses in 
Ghana. Further, the indirect cost (productivity losses due 
to worker absenteeism) was estimated using the national 
daily minimum wage because data on gross salaries of 
staff were not collected due to difficulties in getting these 
from businesses. It is possible that the use of minimum 
wage underestimates the actual indirect costs since many 
businesses pay their staff salaries higher than the national 
daily minimum wage.
In spite of these limitations, this study is an attempt at 
estimating the cost of malaria to businesses in Ghana. 
Further studies are needed to estimate the impact of 
malaria-specific corporate spending on the growth and 
returns of businesses. This would require time series data 
to effectively model such relationship. Thus, businesses 
would have to consistently keep records on disease-
specific morbidity and expenditure associated with such 
morbidity.
Conclusions
The current study has estimated the total cost of malaria 
to businesses in Ghana in 2014 to be US$6.58 million, 
90 % of which were direct costs. Further, a total of 3913 
workdays were lost due to malaria in firms in the study 
sample during the period 2012–2014, with an annual 
average of 1304. The study further estimates that busi-
nesses in the study sample spent an average of 0.5  % of 
the annual corporate returns on treatment of malaria in 
employees and their dependants, 0.3  % on malaria pre-
vention, and 0.5  % on other health-related corporate 
social responsibilities. Business leaders affirmed that 
malaria affects their businesses’ efficiency, employee 
attendance and productivity and expenses. Finally, major-
ity of business leaders expressed the need for increased 
government investments in malaria control and most 
of them concurred that it is worthwhile for their busi-
nesses to invest in malaria control. Thus, business leaders 
do acknowledge the effect of malaria morbidity on their 
operations and ultimately their income and workforce. 
This acknowledgement provides motivation for the pri-
vate sector to be engaged in malaria control activities.
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